看多
Anthera Pharmaceuticals- It can only be long
Everything says this is bullish to me, at least for the short term.
Fundamentally, Anthera have today announced the successful completion of an interim analysis of its Phase 3 trial (CHABLIS-SC1) of blisibimod in patients with Systemic Lupus Erythematosus and that the study should continue to completion as planned. This is a critical milestone for the company.
In terms of technical analysis, The only problem is the historical resistance zone I've discovered (The black line going across the chart.)
I'm looking to take profits very quickly in case of a turn around and have a stop loss in place.
Break above the 200 EMA and the Slow curve pattern as well as the trendline resistance tells me this is a home run.
I took an aggressive entry and got filled at 3.29 so I've already hit a complete home run here.
Good luck traders.
Fundamentally, Anthera have today announced the successful completion of an interim analysis of its Phase 3 trial (CHABLIS-SC1) of blisibimod in patients with Systemic Lupus Erythematosus and that the study should continue to completion as planned. This is a critical milestone for the company.
In terms of technical analysis, The only problem is the historical resistance zone I've discovered (The black line going across the chart.)
I'm looking to take profits very quickly in case of a turn around and have a stop loss in place.
Break above the 200 EMA and the Slow curve pattern as well as the trendline resistance tells me this is a home run.
I took an aggressive entry and got filled at 3.29 so I've already hit a complete home run here.
Good luck traders.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。